Godište 35 supplement 2 - Institut za reumatologiju

3. Liu Y, Linsley PS. Co stimulation of T-cell growth. Curr Opin Immunol 1992; 4:265
4. Schwartz, RH. Co stimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in
interleukin-2 production and immunotherapy. Cell 1992; 71:1065
5. Wagner UG, Kurtin PJ, Wahner A. The role of CD8+ CD40L+ cells in the formation of germinal
centres in rheumatoid synovitis. J Immunol 1998; 161: 3690-7
6. Coch AE. Review :angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41:
951-62
7. Litter AJ, Buckley CD, Wordsworth P, Collins J, Martinson J, Simmons DL. Distinkt profile of
six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E selecting, L selectin and P
selectin ) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164-9
8. Nassonov EL, Samsonov MY, Chichanova NV, Nikiphorova EL, Tilz GP, Demel U. Soluble
adhesion molecules in rheumatoid arthritis. Rheumatology 2000; 39: 808-10
9. Klimiuk PA, Sierakowski S, Latosiewicz JP, at all. Soluble adhesion molecules (ICAM-1,
VCAM-1 and E selectin) and vascular endothelial growth factor (VEGF) in patients with distinct
variants of rheumatoid synovitis. Ann Rheum Dis 2002; 61: 804-9
10. Morales-Ducret, J, Wayner, E, Alices, MJ, et al. a4/b1 integrin (VLA-4) ligands in arthritis:
vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J
Immunol 1992; 149:1424
11. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and
chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum
Dis 2003; 62: 715-21
12. Buckley CD, Filer A, O Haworth, G Parsonage, Salmon M. Defining a role for fibroblasts in the
persistence of chronic inflammatory joint disease. Ann Rheum Dis 2004; 63(suppl II):ii92-ii95
13. Smeets TJM, Barg EC, Kraan MC, Smith MD, Beedvelol FC, Tak PP. Analysis of the cell
infiltrate and expression of proinflamatory cytokines and matrix metalloproteinases in
arthroskopic synovial biopsies: comparison with synovial samples from patients with end stage,
destructive rheumatoid arthritis. Ann Rheum Dis 2003; 62: 635-8
14. Weyand CM. New insight into the pathogenesis of rheumatoid arthritis. Rheumatology 2000; 39
(suppl 1): 3-8
15. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45:
101-6
16. Ronney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C. Analysis of histologic
variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988; 31: 956-63
17. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis.
Rheumatology 2003; 42(Suppl 2):ii11-16
18. Murphy G, Knauper V, Atkinson S, Bufler G, English W, Hutton M. Matrix metaloproteinases in
arthritis disease. Arthritis Res 2002;4(suppl): S39-S49
19. I Ospelt C. Kyburz D, Pierer M, Seibl R, Kurowska M, Distler O, Neidhard M, Muller-Ladner U,
Pap T, Gay RE, Gay S. Toll-like receptors in rheumatoid arthritis joint destruction mediated by
two distinct pathways. Ann Rheum Dis 2004; 63(suppl II): ii 90-ii91
20. Gough A, Sambrook P, Devlin J, et al: Osteoclastic activation is the principal mechanism leading
to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 7:1282–1289
21. Gravallese EM, Harada Y, Wang JT, et al: Identification of cell types responsible for bone
resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152:943–
51
22. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in
rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum
2000; 43:250-8.